Qiagen (NYSE:QGEN) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Qiagen (NYSE:QGEN) have received a consensus recommendation of “Moderate Buy” from the nine analysts that are covering the firm, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price target among analysts that have covered the stock in the last year is $51.10.

Several brokerages have commented on QGEN. Wolfe Research upgraded shares of Qiagen from a “peer perform” rating to an “outperform” rating and set a $50.00 target price for the company in a research report on Thursday, June 27th. Robert W. Baird upped their price objective on Qiagen from $49.00 to $52.00 and gave the company an “outperform” rating in a report on Friday, August 2nd. Finally, JPMorgan Chase & Co. increased their target price on Qiagen from $52.00 to $54.00 and gave the company an “overweight” rating in a research note on Tuesday, June 18th.

Hedge Funds Weigh In On Qiagen

Several institutional investors and hedge funds have recently modified their holdings of QGEN. Riverview Trust Co acquired a new position in Qiagen in the 1st quarter worth $28,000. Toronto Dominion Bank bought a new stake in shares of Qiagen in the second quarter valued at about $27,000. Park Place Capital Corp bought a new stake in shares of Qiagen in the first quarter valued at about $36,000. Quarry LP acquired a new position in shares of Qiagen during the fourth quarter worth about $38,000. Finally, CWM LLC grew its holdings in shares of Qiagen by 19.1% during the first quarter. CWM LLC now owns 2,236 shares of the company’s stock worth $96,000 after buying an additional 358 shares in the last quarter. 70.00% of the stock is currently owned by institutional investors and hedge funds.

Qiagen Stock Up 0.0 %

Shares of QGEN opened at $45.90 on Friday. The business’s fifty day moving average price is $44.14 and its two-hundred day moving average price is $43.35. The firm has a market capitalization of $10.47 billion, a price-to-earnings ratio of 30.81, a PEG ratio of 3.17 and a beta of 0.39. Qiagen has a 52 week low of $34.74 and a 52 week high of $47.44. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.46 and a current ratio of 1.77.

Qiagen (NYSE:QGEN) last posted its quarterly earnings results on Wednesday, July 31st. The company reported $0.55 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.52 by $0.03. The business had revenue of $496.00 million for the quarter, compared to analysts’ expectations of $495.45 million. Qiagen had a return on equity of 12.92% and a net margin of 3.75%. The firm’s quarterly revenue was down .2% compared to the same quarter last year. During the same quarter last year, the business earned $0.53 earnings per share. On average, analysts predict that Qiagen will post 2.15 earnings per share for the current year.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.